• Source: Sinopharm (company)

China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.), Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.




History


Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).
Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.
Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seep approval for 12 drugs in China through 2025.




COVID-19 vaccines



The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group). In December 2020, the UAE previously announced interim results showing 86% efficacy. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia, Africa, South America, and Europe. Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021. On 7 May 2021, the World Health Organization approved the vaccine for emergency use and Sinopharm later signed purchase agreements for 170 million doses from COVAX.
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.




See also


CanSino Biologics
Sinovac




References






External links


Official website

Kata Kunci Pencarian:

• Sinovac Biotech
• GSK plc
• Vaksin Covid-19
• Masker dalam pandemi COVID-19
• CoronaVac
• Ketahanan pangan selama pandemi Covid-19
• Kronologi pandemi Covid-19 Februari 2020
• Tanggapan Uni Eropa terhadap pandemi Covid-19
• Tes penyakit koronavirus 2019
• Pengembangan obat untuk Covid-19
• Sinopharm (company)
• Sinopharm Group
• Sinopharm BIBP COVID-19 vaccine
• Sinopharm (disambiguation)
• Takeda Pharmaceutical Company
• Sinopharm WIBP COVID-19 vaccine
• List of COVID-19 vaccine authorizations
• G42 (company)
• List of pharmaceutical companies
• List of largest biomedical companies by revenue